P
Peter S. Nelson
Researcher at Fred Hutchinson Cancer Research Center
Publications - 497
Citations - 57568
Peter S. Nelson is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 96, co-authored 425 publications receiving 47923 citations. Previous affiliations of Peter S. Nelson include University of Washington & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Paracrine Wnt signaling is necessary for prostate epithelial proliferation
Xing Wei,Martine Roudier,Oh-Joon Kwon,J. D. Lee,Kevin Kong,Ruth Dumpit,Lawrence D. True,Colm Morrissey,Daniel W. Lin,Peter S. Nelson,Li Xin +10 more
TL;DR: The Wnt proteins play key roles in the development, homeostasis, and disease progression of many organs including the prostate, but the spatiotemporal expression patterns remain inadequately characterized.
Journal Article
Delayed Dark Adaptation in 11–cis–retinol Dehydrogenase Deficient Mice: A Role of RDH11 in Visual Processes in vivo
TL;DR: It is suggested that RDH11 has a measurable role in regenerating the visual pigment by complementing RDH5 as an 11-cis-RDH in RPE cells, and indicate that an additional unidentified enzyme(s) oxidizes 11- cis-retinol or that an alternative pathway contributes to the retinoid cycle.
Journal ArticleDOI
Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr1) gene, a new member of the short-chain steroid dehydrogenase/reductase family.
TL;DR: Together, the isolation and characterization of a complementary DNA (cDNA) encoding a novel member of the short-chain dehydrogenase/reductase (SDR) gene family that is involved in the tissue-specific metabolism of retinoids or steroid hormones are described.
Journal ArticleDOI
Neoadjuvant androgen pathway suppression prior to prostatectomy.
Elahe A. Mostaghel,Peter S. Nelson,Paul H. Lange,Daniel W. Lin,Mary-Ellen Taplin,Steven P. Balk,William J. Ellis,Trevor M. Penning,Brett T. Marck,Lawrence D. True,Robert L. Vessella,Robert B. Montgomery +11 more
TL;DR: This study determined whether targeting androgen metabolism using CYP17 and 5a-reductase (SRD5A) inhibitors would more effectively suppress tissue androgens and tumor volume in men with intermediate/high risk PCa.
Journal ArticleDOI
Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages
Hemanth Potluri,Tun Lee Ng,Michael A. Newton,Jin Zhang,Christopher G. Maher,Peter S. Nelson,Douglas G. McNeel +6 more
TL;DR: The longitudinal data showed that treatments can elicit antibodies detectable by this peptide array, and notably vaccine-treated patients developed increased responses to more proteins over the course of treatment than did ADT- treated patients.